Which option best depicts prolonged disease care

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. [PubMed] [Google Scholar]

2. National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER). 2017. http://www.seer.cancer.gov. Accessed March 23, 2017.

3. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765. [PubMed] [Google Scholar]

4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060. [PubMed] [Google Scholar]

5. Hernández JM, García-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127:159–164. [PubMed] [Google Scholar]

6. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259–2266. [PubMed] [Google Scholar]

7. Benboubker L, Dimopoulos MA, Dispenzieri A, et al.; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–917. [PubMed] [Google Scholar]

8. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128. [PMC free article] [PubMed] [Google Scholar]

9. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16:1600–1603. [PMC free article] [PubMed] [Google Scholar]

10. Warren JL, Harlan LC, Stevens J, et al. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013;31:1984–1989. [PMC free article] [PubMed] [Google Scholar]

11. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–1831. [PubMed] [Google Scholar]

12. Gay F, Palumbo A. Management of older patients with multiple myeloma. Blood Rev. 2011;25:65–73. [PubMed] [Google Scholar]

13. Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015;21:701–706. [PMC free article] [PubMed] [Google Scholar]

14. Garcia CM, Mumby PB, Thilges S, et al. Comparison of early quality of life outcomes in autologous and allogeneic transplant patients. Bone Marrow Transplant. 2012;47:1577–1582. [PubMed] [Google Scholar]

15. Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol. 2010;148:373–385. [PMC free article] [PubMed] [Google Scholar]

16. Lee SJ, Fairclough D, Parsons SK, et al. Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol. 2001;19:242–252. [PubMed] [Google Scholar]

17. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30:71–77. [PMC free article] [PubMed] [Google Scholar]

18. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980–987. [PMC free article] [PubMed] [Google Scholar]

19. Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M157. [PubMed] [Google Scholar]

20. Larocca A, Bringhen S, Petrucci MT, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia. 2016;30:1320–1326. [PubMed] [Google Scholar]

21. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–2074. [PMC free article] [PubMed] [Google Scholar]

22. Rubenstein LZ, Stuck AE, Siu AL, et al. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc. 1991;39 (pt 2):8S–16S; discussion 17S-18S. [PubMed] [Google Scholar]

23. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–3465. [PMC free article] [PubMed] [Google Scholar]

24. Lagro J, Timmer-Bonte J, Maas HA. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer and the importance of geriatric assessment. J Clin Oncol. 2012;30:4443–4445, author reply 4443–4445. [PubMed] [Google Scholar]

25. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–3386. [PubMed] [Google Scholar]

26. Guralnik JM, Seeman TE, Tinetti ME, et al. Validation and use of performance measures of functioning in a non-disabled older population: MacArthur studies of successful aging. Aging (Milano). 1994;6:410–419. [PubMed] [Google Scholar]

27. Klepin HD, Rizzieri D, Palumbo A, et al. Individualizing treatment decisions for older adults with hematologic malignancies. Am Soc Clin Oncol Educ Book. 2013;33:208–219. [PubMed] [Google Scholar]

28. Rantanen T, Masaki K, Foley D, et al. Grip strength changes over 27 yr in Japanese-American men. J Appl Physiol (1985). 1998;85:2047–2053. [PubMed] [Google Scholar]

29. Sasaki H, Kasagi F, Yamada M, et al. Grip strength predicts cause specific mortality in middle-aged and elderly persons. Am J Med. 2007;120:337–342. [PubMed] [Google Scholar]

30. Chang YJ, Lee JS, Lee CG, et al. Assessment of clinical relevant fatigue level in cancer. Support Care Cancer. 2007;15:891–896. [PubMed] [Google Scholar]

31. McDowell I Measuring Health: A Guide to Rating Scales and Questionnaires, 3rd ed New York: Oxford University Press; 2006. [Google Scholar]

32. Prieto JM, Blanch J, Atala J, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20:1907–1917. [PubMed] [Google Scholar]

33. Tomaka J, Thompson S, Palacios R. The relation of social isolation, loneliness, and social support to disease outcomes among the elderly. J Aging Health. 2006;18:359–384. [PubMed] [Google Scholar]

34. Molassiotis A, van den Akker OB, Boughton BJ. Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors. Soc Sci Med. 1997;44:317–325. [PubMed] [Google Scholar]

35. Meehan KR, Fitzmaurice T, Root L, et al. The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol. 2006;4:187–190. [PubMed] [Google Scholar]

36. Jacobs SR, Small BJ, Booth-Jones M, et al. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer. 2007;110:1560–1567. [PubMed] [Google Scholar]

37. Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009;23:1131–1138. [PubMed] [Google Scholar]

38. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3819–3829. [PubMed] [Google Scholar]

39. El-Banna MM, Berger AM, Farr L, et al. Fatigue and depression in patients with lymphoma undergoing autologous peripheral blood stem cell transplantation. Oncol Nurs Forum. 2004;31:937–944. [PubMed] [Google Scholar]

40. Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin. 2010;60:120–132. [PubMed] [Google Scholar]

41. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007;25:1936–1944. [PubMed] [Google Scholar]

42. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38:275–283. [PubMed] [Google Scholar]

43. Wildes TM, Ruwe AP, Fournier C, et al. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol. 2013;4:227–234. [PMC free article] [PubMed] [Google Scholar]

44. Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101: 1110–1119. [PMC free article] [PubMed] [Google Scholar]

45. Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1:e35. [PMC free article] [PubMed] [Google Scholar]

46. Kleber M, Ihorst G, Gross B, et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013;13:541–551. [PubMed] [Google Scholar]

47. Mohile SG, Velarde C, Hurria A, et al. Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts. J Natl Compr Canc Netw. 2015;13:1120–1130. [PMC free article] [PubMed] [Google Scholar]

48. Mühlbacher AC, Nübling M. Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur J Health Econ. 2011;12:193–203. [PubMed] [Google Scholar]

49. van der Poel MW, Oerlemans S, Schouten HC, et al. Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol. 2015;94:651–661. [PubMed] [Google Scholar]

50. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79. [PMC free article] [PubMed] [Google Scholar]

51. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:171–184. [PubMed] [Google Scholar]

52. Kent EE, Ambs A, Mitchell SA, et al. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121:758–765. [PMC free article] [PubMed] [Google Scholar]

53. Delforge M, Minuk L, Eisenmann JC, et al. Health-related quality of life (HRQOL) in patients (pts) with newly diagnosed multiple myeloma (NDMM): the first trial. Haematologica. 2014;99:109–110. [Google Scholar]

54. Delforge M, Dhawan R, Robinson D Jr, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89:16–27. [PubMed] [Google Scholar]

55. Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959–1969. [PMC free article] [PubMed] [Google Scholar]

56. Bhutani M, Landgren O, Usmani SZ. Multiple myeloma: is it time for biomarker-driven therapy? Am Soc Clin Oncol Educ Book. 2015;35:e493–e503. [PubMed] [Google Scholar]

57. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. J Clin Oncol. 2014;32:2611–2616. [PMC free article] [PubMed] [Google Scholar]

58. Rosko A, Hofmeister C, Benson D, et al. Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma. Bone Marrow Transplant. 2015;50:1379–1381. [PMC free article] [PubMed] [Google Scholar]

59. Milani P, Vincent Rajkumar S, Merlini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91:1129–1134. [PMC free article] [PubMed] [Google Scholar]

60. LaPak KM, Burd CE. The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res. 2014;12:167–183. [PMC free article] [PubMed] [Google Scholar]

61. Liu Y, Johnson SM, Fedoriw Y, et al. Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood. 2011;117:3257–3267. [PMC free article] [PubMed] [Google Scholar]

62. Melzer D, Frayling TM, Murray A, et al. A common variant of the p16(INK4a) genetic region is associated with physical function in older people. Mech Ageing Dev. 2007;128:370–377. [PMC free article] [PubMed] [Google Scholar]

63. Zeggini E, Weedon MN, Lindgren CM, et al.; Wellcome Trust Case Control Consortium (WTCCC). Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336–1341. [PMC free article] [PubMed] [Google Scholar]

64. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–1493. [PubMed] [Google Scholar]

65. Liu Y, Sanoff HK, Cho H, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8:439–448. [PMC free article] [PubMed] [Google Scholar]

66. Zindy F, Soares H, Herzog KH, et al. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development. Cell Growth Differ. 1997;8:1139–1150. [PubMed] [Google Scholar]

67. Ressler S, Bartkova J, Niederegger H, et al. p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell. 2006;5:379–389. [PubMed] [Google Scholar]

68. Wood WA, Krishnamurthy J, Mitin N, et al. Chemotherapy and stem cell transplantation increase p16(INK4a) expression, a biomarker of T-cell aging. EBioMedicine. 2016;11:227–238. [PMC free article] [PubMed] [Google Scholar]

69. Majhail NS, Farnia SH, Carpenter PA, et al.; American Society for Blood and Marrow Transplantation. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863–1869. [PMC free article] [PubMed] [Google Scholar]

70. Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2015. http://www.cibmtr.org. Accessed March 23, 2016.

71. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28:2612–2624. [PubMed] [Google Scholar]

72. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775–5782. [PubMed] [Google Scholar]

73. Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12:286–295. [PMC free article] [PubMed] [Google Scholar]

74. Paiva B, Vidriales MB, Cerveró J, et al.; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–4023. [PMC free article] [PubMed] [Google Scholar]

75. Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125:1932–1935. [PMC free article] [PubMed] [Google Scholar]

76. Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21:335–341. [PMC free article] [PubMed] [Google Scholar]

77. Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209–215. [PubMed] [Google Scholar]

78. Sharma M, Zhang MJ, Zhong X, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20:1796–1803. [PMC free article] [PubMed] [Google Scholar]

79. Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34:356–359. [PMC free article] [PubMed] [Google Scholar]

80. Nath CE, Trotman J, Tiley C, et al. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol. 2016;82:149–159. [PMC free article] [PubMed] [Google Scholar]

81. Majhail NS, Omondi NA, Denzen E, et al. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2010;16:1070–1075. [PMC free article] [PubMed] [Google Scholar]

82. Shah N, Callander N, Ganguly S, et al.; American Society for Blood and Marrow Transplantation. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1155–1166. [PubMed] [Google Scholar]

83. Reuben DB, Rubenstein LV, Hirsch SH, et al. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med. 1992;93:663–669. [PubMed] [Google Scholar]

84. Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402–408. [PMC free article] [PubMed] [Google Scholar]

85. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–2869. [PMC free article] [PubMed] [Google Scholar]

86. Beattie S, Lebel S, Tay J. The influence of social support on hematopoietic stem cell transplantation survival: a systematic review of literature. PLoS One. 2013;8:e61586. [PMC free article] [PubMed] [Google Scholar]

87. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35. [PMC free article] [PubMed] [Google Scholar]

88. Paiva B, Vídriales MB, Rosiñol L, et al.; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013;27:2056–2061. [PubMed] [Google Scholar]

89. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025–3031. [PubMed] [Google Scholar]

90. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. [PubMed] [Google Scholar]

91. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28:391–397. [PubMed] [Google Scholar]

92. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073–3079. [PMC free article] [PubMed] [Google Scholar]

93. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–2547. [PubMed] [Google Scholar]

94. de Tute RM, Rawstron AC, Gregory WM, et al. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica. 2016;101:e69–e71. [PMC free article] [PubMed] [Google Scholar]

95. Mateos MV, Oriol A, Martínez-López J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014;124:1887–1893. [PubMed] [Google Scholar]

96. Paiva B, Cedena MT, Puig N, et al.; Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127:3165–3174. [PubMed] [Google Scholar]

97. Paiva B, Montalbán MA, Puig N, et al. Clinical significance of sensitive flow-MRD monitoring in elderly multiple myeloma patients on the PETHEMA/GEM2010MAS65 Trial. Blood. 2014;124:3390–3390. [Google Scholar]

98. Mateos MV, Ocio EM, Paiva B, et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 2015;29:387–403. [PubMed] [Google Scholar]

99. Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open label, phase 3 trial. Lancet. 2017;389:519–527. [PMC free article] [PubMed] [Google Scholar]

Page 2

Clinical Examples of Geriatric Assessment Metrics